Founded in 2005, Dragon Boat Pharmaceutical is a high-tech enterprise committed to the research and development of biologics. We focus on the therapeutic area for gastrointestinal cancer and are dedicated to bringing novel drugs for treating oncology and autoimmune disease to global patients. The company was wholly owned by Guilin Sanjin (002275) since 2013.
Adhering to the concept of independent innovation, we established a drug R&D center in Zhangjiang high-tech park, occupying 5,000 square meters, covering early discovery, preclinical research, IND, clinical research, BLA and manufacturing. Our pipeline has 9 biologics candidates, covering multiple modalities and multiple immune targets. As of today, 4 of them entered the clinical development stage. With insistent investment to R&D and excellent drug discovery capability, Dragon boat Pharmaceutical became a leading innovative biotech company in China.
Innovation for a healthier world
Seasoned manager with over 15 years’ experience in biologics R&D. He led dozens of preclinical and clinical programs of therapeutic antibodies in Fudan Zhang Jiang and Dragon Boat. He is also expert in pharmacology and process development. Huang holds a P
With over 10-years’ experience in R&D and quality management of biologics, she served as a research scientist at NUS and A*Star Singapore before joining Dragon Boat Biopharmaceutical. She is specializing in analytical testing and quality management. Shao
Regulatory expert with over 16 years’ experience in regulatory affairs for biosimilar and new drug development. She was the former leader of Regulatory Affairs at Henlius and successfully submitted and maintained major regulatory applications to NMPA, inc
Having extensive experience in financing and investing in the biotech and pharmaceutical industry, Ruan was once the long-term director of fund-raising & investment at Guilin Sanjin. Ruan graduated from Tongji Medical College of Huazhong University of Sci
Dragon Boat is proud to be recognized by the government and some of the most influential organizations.
An in-house developed biosimilar of etanercept was licensed to Merck Serono (EU),
which has exclusive rights for developing, manufacturing, and commercializing the
candidate.
Fully acquired as a subsidiary company of TCM producer, Guilin Sanjin Pharmaceutical, and changed company name to Dragon Boat Biopharmaceuticals.
Received first NMPA IND approval for the lead candidates BC001 in China.
China’s first anti-CSF-1R antibody (BC006) entered clinical-stage
Founded in Shanghai under the name of Dragonfly Sciences as a contract research
organization.
Transformed into a biotech company and devoted to contributing to human health by
developing novel antibody drugs.
